BACKGROUND: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis.
Adalimumab is a fully human monoclonal immunoglobulin G1 antibody that neutralizes …

The introduction of the biologic agents, adalimumab, etanercept, infliximab and
ustekinumab, has provided more options for the short‐and long‐term treatment of patients …

Background Infiximab has been shown to be highly effective in phase III clinical trials, but
limited information is available regarding drug survival and maintenance of efficacy beyond …

RESULTS A total of 85 patients (55 (65%) males, 30 (35%) females; mean age 51±13.6
years) were included in the study. Patients' mean psoriasis duration was 21.7±10.8 years …

Background: Adalimumab, a fully human monoclonal antibody, binds to and neutralizes
tumor necrosis factor. Objective: To provide an integrated review of efficacy and safety from …

Cutaneous and articular psoriasis usually have a more complicated course in patients
chronically infected by human immunodeficiency virus (HIV), not only for its particular …

Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation
in therapy for psoriasis. However, a significant number of psoriasis patients do not respond …

Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute …

Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …

Background Limited information is available regarding factors associated with long‐term
drug survival of infliximab for psoriasis in real life. Objectives The main aim pf this study was …